* Transmedics Group Inc TMDX.OQ TMDX.O is expected
to show a
rise in quarterly revenue when it reports results on August 3.
* The Andover Massachusetts-based company is expected to
report
a 106.7% increase in revenue to $42.42 million from $20.52
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Transmedics Group
Inc is
for a loss of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Transmedics
Group
Inc is $92.5, below its last closing price of $93.88.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.21 -0.25 -0.08 Beat 67.5
Dec. 31 2023 -0.30 -0.30 -0.21 Beat 30
Sep. 30 2022 -0.43 -0.41 -0.25 Beat 39.3
Jun. 30 2022 -0.35 -0.35 -0.41 Missed -17.8
Mar. -0.39 -0.38 -0.38 Met 0
31 2022
Dec. 31 2021 -0.43 -0.42 -0.46 Missed -8.5
Sep. 30 2021 -0.36 -0.36 -0.47 Missed -32
Jun. 30 2021 -0.28 -0.28 -0.39 Missed -38.3
This summary was machine generated August 2 at 02:09 GMT. All
figures in US dollars unless otherwise stated